Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COVIVAC + CpG 1018
- Development stage
- Unknown
- Lead developer
- Institute of Vaccines and Medical Biologicals
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
COVIVAC + CpG 1018 is a **combination recombinant protein subunit COVID-19 vaccine** that uses the COVIVAC antigen—a stabilized prefusion SARS-CoV-2 spike protein (recombinant protein)—adjuvanted with CpG 1018, a synthetic oligodeoxynucleotide that acts as a toll-like receptor 9 (TLR9) agonist. CpG 1018 is used to bias the immune response towards a Th1 profile, enhancing cellular immunity and boosting antibody responses. COVIVAC has been developed by the Institute of Vaccines and Medical Biologicals (IVAC) in Vietnam. The addition of CpG 1018, developed by Dynavax, is intended to further improve immunogenicity, antibody titers, and shift the response away from Th2, reducing the risk of adverse immune reactions such as eosinophilic infiltration. Clinical studies indicate this formulation is safe, with mostly mild adverse events, and induces robust neutralizing antibody and IgG responses in adults[4][6][1][2].
- Other names
- CoviVac CpGIVAC SARS-CoV-2 vaccine CpG
02
Targets
TLR9 (Toll-like receptor 9)SARS-CoV-2 spike
Beyond the preview
Go deeper on COVIVAC + CpG 1018.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COVIVAC + CpG 1018.